ARCA biopharma Topline Results Miss in ASPEN-COVID-19 Phase 2b

 

• For the entire cohort of COVID-19 hospitalized patients, the pooled lower and higher rNAPc2 dose groups demonstrated a reduction compared to baseline in D-dimer levels of 16.8% versus 11.2% for standard of care heparin which was not statistically significant and consequently did not achieve the study primary endpoint

• The treatment effects of rNAPc2 and heparin were different in Mild versus Severe categories of an adapted WHO COVID-19 Severity Scale, with generally decreasing D-dimer levels from baseline in Mild patients, but in Severe patients D-dimer levels were increasing in the Heparin group with no change in the rNAPc2 groups

• rNAPc2 was well-tolerated at both doses

• Company is now evaluating options for development of its assets, including partnering and other strategic options

https://finance.yahoo.com/news/arca-biopharma-reports-topline-results-201500436.html